Ahead of print

Review

Mirvetuximab Soravtansine and its Treatment-Associated Ocular Adverse Effects. A Review of the Current Knowledge

Pavel Studený ORCID
Enkela Hrdličková

Full Text links

Keywords: mirvetuximab soravtansine, ADC, keratopathy, ocular adverse events, cornea, ovarian cancer

Summary

Mirvetuximab soravtansine is an antibody–drug conjugate targeting folate receptor alpha (FRα), which is used in the treatment of platinum-resistant ovarian cancer. Its administration is associated with a distinct spectrum of ocular adverse events, representing a clinically relevant limitation of therapy. The most common manifestations include keratopathy, blurred vision, and dry eye symptoms. These effects are generally reversible and manageable upon appropriate ophthalmologic monitoring. This review summarizes the current knowledge regarding the mechanisms, clinical presentation, incidence, prevention, and management of mirvetuximab-associated ocular toxicity.

References

  1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLO- BOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
  2. Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284-296.
  3. Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337.
  4. Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet. 2019;394(10200):793-804.
  5. Schwörer I, Huwer S, Rautenberg B, Neubauer J, Juhasz-Böss I, Jung L. Treatment with mirvetuximab soravtansine: first clinical experience in advanced ovarian cancer. Front Oncol. 2026;16:1732304.
  6. McRae C, Cowan R, Green M, Parker JS. Intraepithelial corneal deposits associated with mirvetuximab soravtansine use for platinum-resistant ovarian cancer. Am J Ophthalmol Case Rep. 2025;38:102271.
  7. Hendershot A, Slabaugh M, Riaz KM, et al. Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine. Gynecol Oncol Rep. 2023;47:101155.
  8. Moore KN, Lorusso D, Oaknin A, et al. Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: an integrated safety summary. Gynecol Oncol. 2024;191:249-258.
  9. Matulonis UA, Lorusso D, Oaknin A et al. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study. J Clin Oncol. 2023 May 1;41(13):2436-2445.
  10. Dilawari A, Shah M, Ison G, et al. FDA approval summary: mirvetuximab soravtansine-gynx for FRα-positive, platinum-resistant ovarian cancer. Clin Cancer Res. 2023;29(19):3835-3840.
  11. Mao K, Chen P, Sun H et al. Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS). Front Pharmacol. 2024 Aug 20;15:1425617.
  12. Zhang J, Li M, Yang Y et al. Single-Cell Transcriptomics Reveals a Multi-Compartmental Cellular Cascade Underlying Elahere-Induced Ocular Toxicity in Rats. Pharmaceuticals (Basel). 2025 Oct 4;18(10):1492.
  13. Marshall R, Xu H, Dalvin LA et al. Accuracy and Completeness of Large Language Models About Antibody-Drug Conjugates and Associated Ocular Adverse Effects. Cornea. 2024 Aug 7;44(7):851-
  14. Aschenbrenner DS. New Drug Treats Female Reproductive Cancers. Am J Nurs. 2023 Apr 1;123(4):25.
  15. De Dominicis F, Giudiceandrea A, Cocuzza M, Bruzio S, Fasciani R, Mosca L, et al. Corneal toxicity of mirvetuximab soravtansine: multimodal imaging features and implications for ophthalmologic management. Diagnostics (Basel). 2026;16(7):1107.
  16. Canestraro J, Kowalsky Moskaliuk D, Abramson DH, Francis JH. Mirvetuximab soravtansine-gynx induced anterior uveitis: a case series. Ocul Immunol Inflamm. 2026;34(1):73-75.
  17. Coleman RL, Lorusso D, Oaknin A et al. Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial. Int J Gynecol Cancer. 2024 Aug 5;34(8):1119-1125.
  18. File B, Hari A, Bei L. Dehydrated amniotic membrane patch for the treatment of an ocular event secondary to mirvetuximab soravtansine-gynx therapy. Gynecol Oncol Rep. 2024;56: 101547.